<DOC>
	<DOCNO>NCT02714205</DOCNO>
	<brief_summary>A randomized , double-blinded , placebo-controlled trial uninterrupted transdermal nitrate therapy 140 peri- postmenopausal woman frequent hot flash . Women randomly assign uninterrupted use transdermal nitrate therapy ( participant direct dose-escalation 0.2 0.6 mg/hr ) identical-appearing placebo patch 12 week .</brief_summary>
	<brief_title>Flushing Reduction Associated With Nitrates</brief_title>
	<detailed_description />
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Flushing</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<criteria>Women age 40 62 year ( consistent recent MSFlash hot flash network trial , likely maximize enrollment highly symptomatic woman ) Postmenopausal late menopausal transition . For study , postmenopausal status define : 1 ) selfreported history bilateral oophorectomy , 2 ) follicle stimulate hormone ( FSH ) level &gt; 20 mU/mL selfreported history hysterectomy without bilateral oophorectomy , 3 ) selfreported history hysterectomy oophorectomy , absence menses past 12 month . Late menopausal transition define amenorrhea least 60 day past 12 month within specified age group . Documentation average 7 hot flash per 24 hour well 4 moderatetosevere hot flash per 24 hour record validate 7day screen symptom diary Willing refrain initiating treatment know affect frequency severity hot flash trial period Current recent use NTG nitratecontaining medication ( i.e. , use within 1 month screening ) , intention use nitratecontaining medication interventional period Current recent use medication already know reduce frequency severity hot flash ( e.g. , systemic estrogen progestin past 3 month ; clonidine , methyldopa , gabapentin , selective serotonin norepinephrine reuptake inhibitor ( SSRIs/SNRIs ) past 1 month ) ; intention use medication interventional period Current recent use phosphodiesterase inhibitor medication ( within 1 month screening ) , intention use medication interventional period Selfreported history hypertrophic obstructive cardiomyopathy , aortic valve stenosis , mitral valve stenosis ( conventional contraindication NTG therapy ) Selfreported history coronary disease ( since patient coronary disease may need NTG therapy chest pain may increase risk new coronary event set nitrate tolerance ) Selfreported history diabetes 2 major risk factor coronary disease ( i.e. , smoking , hypertension , hyperlipidemia physicianrecommended pharmacologic treatment ) Hypotension base measure blood pressure &lt; 90/60 baseline ; uncontrolled hypertension base measure blood pressure &gt; 180/110 baseline Selfreported migraine headache require pharmacologic treatment monthly frequent basis ( since may worsen NTG therapy ) Known skin sensitivity adhesive ( may generalize NTG patch ) Unable complete brief 3day runin period involve low available dose NTG ( 0.1 mg/hr ) Currently pregnant , give birth within past 3 month , plan pregnancy study period Unable unwilling provide inform consent , fill questionnaire , complete study visit English Report condition , judgment investigator , render potential participant highly unlikely follow protocol , include plan move , substance abuse , significant psychiatric problem , dementia .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hot flash</keyword>
</DOC>